EIKCS 2021: Future treatments for metastatic kidney cancer

Despite the advances in first-line treatments for metastatic renal cell carcinoma (RCC) over the past few years, new treatments are on the horizon. In a presentation at the European International Kidney Cancer (EIKC) 2021 Virtual Annual Meeting, Dr Hans Hammers from University of Texas Southwestern Medical Center in the USA discussed future treatments for metastatic […]

read more

UK regulator confirms benefits of AstraZeneca vaccine far outweigh the risks

Following suspensions by some countries of the COVID-19 Oxford AstraZeneca COVID-19 vaccine over suspected blood clots, the Medicines and Healthcare Regulatory Authority (MHRA) in the UK confirms that the benefits of the vaccine in preventing COVID-19 far outweigh the risks. People should still go and get their COVID-19 vaccine when asked to do so. Read […]

read more

Cancer Research UK Cancer Patient Experience Survey

Cancer Research UK conducted a survey with cancer patients from across the UK to understand the impact of COVID-19 on their testing, treatment, and care, as well as their day-to-day lives and wellbeing. Nearly 2,000 people completed the survey in May 2020 to explore the impact of the COVID-19 pandemic on cancer patients. From this […]

read more

One Cancer Voice: Plotting a route out of the pandemic and towards world-leading cancer services

Governments across the UK have bold ambitions to improve cancer survival and transform patients’ quality of life for the 1 in 2 of us who will be diagnosed with the disease. Decades of hard work have resulted in cancer survival doubling over the last half a century – now half of people diagnosed with cancer […]

read more

HIF-2α inhibitor belzutifan to be fast-tracked for approval for VHL kidney cancer

Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks […]

read more

Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The European Commission will now review the CHMP recommendation and make a final decision in the next few months […]

read more

Warning over COVID-19 cons

The NHS has teamed up with the police and security agencies to warn the public not to fall victim to con men trying to exploit the coronavirus vaccine campaign. England’s top GP has joined the head of Action Fraud, the National Crime Agency (NCA) and the National Cyber Security Centre (NCSC) in issuing joint advice […]

read more

Past COVID-19 infection provides some immunity but people may still transmit the virus

A Public Health England (PHE) study (SIREN) finds past infection with coronavirus (COVID-19) provides about 83% protection against reinfection (immunity) for at least 5 months from first becoming sick, but people may still carry the virus in their nose and throat and therefore risk transmitting it to others. PHE has been regularly testing tens of […]

read more

Obesity diminishes response to immunotherapy in kidney cancer

In this study, the researchers looked at the interaction between obesity and outcomes in patients taking immune checkpoint inhibitors (anti-PD-1 immunotherapy, e.g. nivolumab, pembrolizumab) for the treatment of renal cell carcinoma (RCC). Seventy-two (72) patients with metastatic RCC were treated with anti–PD-1 immunotherapy (none had been treated with immunotherapy before). Obese patients had poorer progression-free […]

read more

Percutaneous thermoablation for small renal masses

This study looked at the survival of patients suitable for surgery who underwent percutaneous thermoablation as a first-line treatment for small renal masses (stage T1a). Eighty-five patients who were suitable for surgery were included in the study. These patients had 97 kidney masses that were proven to be malignant (cancerous) with a biopsy (T1a). These […]

read more
Showing 1 to 10 of 267 results
  TOP